Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fostamatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK known ✓ | P43405 | 13/20 | 0.93 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.93 |
| ▸ | PLK4 | O00444 | 3/20 | 0.93 |
| ▸ | RET | P07949 | 3/20 | 0.93 |
| ▸ | FLT3 | P36888 | 3/20 | 0.93 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.93 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.93 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.93 |
| ▸ | AURKA | O14965 | 2/20 | 0.93 |
| ▸ | STK16 | O75716 | 2/20 | 0.93 |
| ▸ | MST1R | Q04912 | 2/20 | 0.93 |
| ▸ | TNK1 | Q13470 | 2/20 | 0.93 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.93 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.93 |
| ▸ | ADCK1 | Q86TW2 | 2/20 | 0.93 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.93 |
| ▸ | NEK9 | Q8TD19 | 2/20 | 0.93 |
| ▸ | IRAK3 | Q9Y616 | 2/20 | 0.93 |
| ▸ | LATS1 | O95835 | 1/20 | 0.93 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fostamatinib SCHEMBL29351337 | 0.97 | SYK (1.00) | SYKPTK2PLK4RETFLT3 | |
| Fostamatinib SCHEMBL1201371 | 0.97 | SYK (1.00) | SYKPTK2PLK4RETFLT3 | |
| Fostamatinib SCHEMBL22164570 | 0.96 | SYK (0.99) | SYKPTK2PLK4RETFLT3 | |
| Fostamatinib SCHEMBL16820327 | 0.96 | SYK (0.99) | SYKPTK2PLK4RETFLT3 | |
| SCHEMBL12903954 | 0.95 | SYK (0.85) | SYKPTK2PLK4RETFLT3 | |
| Fostamatinib SCHEMBL28519986 | 0.95 | SYK (0.97) | SYKPTK2PLK4RETFLT3 | |
| SCHEMBL12903952 | 0.94 | SYK (0.85) | SYKPTK2PLK4RETFLT3 | |
| SCHEMBL12903947 | 0.93 | SYK (0.81) | SYKPTK2PLK4RETFLT3 | |
| Fostamatinib SCHEMBL16820330 | 0.93 | SYK (0.92) | SYKPTK2PLK4RETFLT3 | |
| SCHEMBL10167983 | 0.93 | SYK (0.92) | SYKPTK2PLK4RETFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015155-A1 | Deuterated 2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015155-A1 | Deuterated 2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses | DPYD, DUT, TYMP | SYK 2772/4885PTK2 4236/4885PLK4 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.